10-Month-Old With Macular Spreading Rash

Dupilumab is the first targeted treatment for B to receive FDA approval, showing improved remission rates, itch reduction, and lower steroid use in pivotal trial.

PODCAST: Listen to our first episode for new research on bacterial vaginosis, a new treatment option for chronic urticaria, and more.

Explore key insights from the 2025 Revolutionizing Atopic Dermatitis meeting, featuring expert interviews and the latest treatment advancements.

At RAD 2025, Johann Gudjonsson, MD, PhD, discussed the OX-40 pathway’s role in AD, genetic links to disease risk, and promising combination therapies in development.

RAD 2025. Lebrikizumab improved skin clearance, itch, and pigmentation in patients with skin of color and atopic dermatitis, with strong safety data through 24 weeks, according to late-breaking data.

RAD 2025: As expert dermatologist Shahriari explains it, eczema may be just another rash on your schedule but for a patient, it could be the reason they don't leave the house.